Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency

Islatravir (MK-8591) is a high-potency reverse transcriptase translocation inhibitor in development for the treatment of HIV-1 infection. Data from preclinical and clinical studies suggest that ~30% to 60% of islatravir is excreted renally and that islatravir is not a substrate of renal transporters...

Descripción completa

Detalles Bibliográficos
Autores principales: Matthews, Randolph P., Cao, Youfang, Patel, Munjal, Weissler, Vanessa L., Bhattacharyya, Arinjita, De Lepeleire, Inge, Last, Stefanie, Rondon, Juan C., Vargo, Ryan, Stoch, S. Aubrey, Iwamoto, Marian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765080/
https://www.ncbi.nlm.nih.gov/pubmed/36346229
http://dx.doi.org/10.1128/aac.00931-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765080/
https://www.ncbi.nlm.nih.gov/pubmed/36346229
http://dx.doi.org/10.1128/aac.00931-22

Ejemplares similares